ITGB1BP1 Knockout HT29 Polyclonal Cells constitute a CRISPR/Cas9-mediated polyclonal knockout cell population engineered to disrupt the ITGB1BP1 gene in the human colorectal adenocarcinoma cell line HT29. This heterogeneous product provides a loss-of-function model that avoids single-cell clonal artifacts, retaining natural genetic variation within the edited pool. The knockout abrogates expression of ICAP-1, the protein encoded by ITGB1BP1, offering a versatile system for probing integrin signaling and epithelial cell dynamics.
HT29 cells are a widely employed model of intestinal epithelium, derived from a human colorectal adenocarcinoma. These cells harbor well-known driver mutations in APC, TP53, and KRAS, reflecting key genetic lesions in sporadic colorectal cancer. Upon reaching confluence or butyrate exposure, HT29 cells differentiate into enterocyte-like cells, acquiring polarized architecture and brush border enzymes. This differentiation capacity, combined with an intact integrin and Rho GTPase machinery, makes them ideal for examining ITGB1BP1-dependent processes in both undifferentiated and differentiated epithelial states.
ITGB1BP1 encodes ICAP-1, a cytoplasmic adaptor that binds the beta1 integrin tail and acts as a negative regulator of integrin activation. ICAP-1 directly sequesters KRIT1 (CCM1), thereby modulating RhoA/ROCK signaling and actin cytoskeletal organization. Upstream, integrin engagement by ECM ligands such as fibronectin and collagen, along with mechanical stress and SP1-mediated transcription, regulates ICAP-1 expression. Downstream, loss of ICAP-1 enhances phosphorylation of FAK (PTK2) and alters expression of cell cycle regulators p21 and cyclin D1, impacting adhesion, migration, and proliferation through the ITGB1?CKRIT1?CFAK axis.
In the HT29 colorectal cancer context, ITGB1BP1 knockout provides a unique tool for dissecting how aberrant integrin signaling drives epithelial tumor progression. ICAP-1 loss is expected to deepress beta1 integrin activity, amplifying focal adhesion formation and potentially facilitating epithelial-mesenchymal transition (EMT). Because HT29 cells retain differentiation capacity, the knockout also allows study of ICAP-1??s role in junctional integrity and apicobasal polarity during enterocytic maturation. The interplay with KRIT1 further connects this model to endothelial biology, although in colorectal epithelium it primarily informs mechanisms of invasion and metastasis.
Typical applications include cell adhesion assays on fibronectin, wound healing migration, and Transwell invasion to quantify migratory changes. Western blotting for FAK Y397 phosphorylation and KRIT1 levels, immunofluorescence for paxillin and F-actin, and RhoA activity assays illuminate cytoskeletal and signaling alterations. Drug sensitivity testing with 5-fluorouracil or oxaliplatin can uncover roles for ICAP-1 in chemoresistance. These polyclonal knockout cells thus support comprehensive studies in colorectal cancer biology, integrin signaling, and drug discovery. For further details, contact Ascent Research.
